Peter Fritz1, Klaus Bendrat2, Maike Sonnenberg3, Christian Trautmann4, German Ott5, Else Heidemann6, Friedhelm Brinkmann6, Simone Faisst6, Andreas Gerteis4, Hiltrud Brauch7, Matthias Schwab8, Christoph Lindner9, Kay Friedrichs10, Mark Dominik Alscher11, Juergen Dippon12, Axel Niendorf2. 1. Institute of Digital Medicine, Stuttgart, Germany Robert Bosch Hospital, Department of Clinical Pathology, Stuttgart, Germany. 2. Pathology Hamburg-West, Hamburg, Germany. 3. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany maike.sonnenberg@ikp-stuttgart.de. 4. Robert Bosch Hospital, Department of Gynecology, Stuttgart, Germany. 5. Robert Bosch Hospital, Department of Clinical Pathology, Stuttgart, Germany. 6. Onkologischer Schwerpunkt Stuttgart e.V., Stuttgart, Germany. 7. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany. 8. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany Department of Clinical Pharmacology, University Hospital Tubingen, Tubingen, Germany. 9. Agaplesion Diakonieklinikum, Gynecology, Hamburg, Germany. 10. Mammazentrum Hamburg, Hamburg, Germany. 11. Institute of Digital Medicine, Stuttgart, Germany. 12. University of Stuttgart, Institute of Stochastics and Applications, Stuttgart, Germany.
Abstract
BACKGROUND: The well-characterized tubular-type of breast tumors is classified as low-risk breast cancer. PATIENTS AND METHODS: We report on the results of a retrospective analysis on clinical and biological features of 248 tubular breast tumors including follow-up and treatment data from two German series of 21,065 breast cancer cases. The majority of tumors were stage I or stage II, ER- and PR-positive and c-erbB2-negative with a 5-year survival-rate of 96.3%. 51.3% of patients received hormonal treatment, 75.5% had post-operative radiotherapy and 11.8% were treated with a chemotherapeutical regimen. CONCLUSION: Our retrospective analysis showed no treatment benefit for either anti-hormonal or chemotherapeutical regimens. Post-operative radiotherapy, however, improved the survival rate of patients with tubular carcinoma (log-rank=5, p=0.025). Our data suggest that post-operative radiotherapy is an important treatment to prolong survival for patients suffering from tubular breast cancer. Copyright
BACKGROUND: The well-characterized tubular-type of breast tumors is classified as low-risk breast cancer. PATIENTS AND METHODS: We report on the results of a retrospective analysis on clinical and biological features of 248 tubular breast tumors including follow-up and treatment data from two German series of 21,065 breast cancer cases. The majority of tumors were stage I or stage II, ER- and PR-positive and c-erbB2-negative with a 5-year survival-rate of 96.3%. 51.3% of patients received hormonal treatment, 75.5% had post-operative radiotherapy and 11.8% were treated with a chemotherapeutical regimen. CONCLUSION: Our retrospective analysis showed no treatment benefit for either anti-hormonal or chemotherapeutical regimens. Post-operative radiotherapy, however, improved the survival rate of patients with tubular carcinoma (log-rank=5, p=0.025). Our data suggest that post-operative radiotherapy is an important treatment to prolong survival for patients suffering from tubular breast cancer. Copyright
Authors: Gerhard Stauch; Peter Fritz; Rauofi Rokai; Atiq Sediqi; Haroon Firooz; Hans Ullrich Voelker; Michael Weinhara; Joachim Mollin; Bishara Soudah; Peter Dalquen; Friedhelm Brinckmann; Jürgen Dippon Journal: Int J Breast Cancer Date: 2021-07-30